CRISPR Antivirals for Chronic Infection: Mechanisms, Clinical Insights, and Emerging Therapeutic Potential

Abstract

Chronic viral infections continue to pose a significant challenge to global health, with current antiviral strategies often limited by issues of drug resistance, persistent viral reservoirs, and incomplete viral eradication. The advent of CRISPR-based technologies has sparked interest in their application as precise, mechanism-driven antivirals targeting the genomes of persistent viruses. This article reviews the clinical and scientific landscape of CRISPR antivirals for chronic infections, focusing on molecular mechanisms, recent research, therapeutic potential, challenges, and future directions relevant to clinicians and healthcare professionals.

Introduction

Chronic viral infections such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), and herpesviruses affect millions globally, leading to significant morbidity and mortality. Despite advances in antiviral pharmacotherapy, the inability to achieve complete viral clearance remains a central obstacle, necessitating lifelong therapy in many patients. Genome-editing technologies, particularly CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), have emerged as promising tools for the direct targeting and inactivation of viral DNA or RNA, offering novel therapeutic approaches for chronic infection management. This review examines the current evidence, clinical relevance, and future scope of CRISPR-based antivirals in the context of chronic infectious diseases.

Epidemiology / Disease Burden

Chronic infections, especially those caused by HBV, HIV, and herpesviruses, account for a substantial proportion of global infectious disease burden. According to the World Health Organization, approximately 296 million people are living with chronic HBV infection, and 38 million with HIV, both of which are associated with long-term complications such as cirrhosis, hepatocellular carcinoma, and AIDS-defining illnesses. Persistent infection is maintained by stable viral reservoirs, including covalently closed circular DNA (cccDNA) in HBV and integrated proviral DNA in HIV, challenging the effectiveness of traditional antiviral drugs and underscoring the need for innovative therapeutic strategies.

Pathophysiology

Chronic viral infections are characterized by the persistence of viral genomes within host cells, evading immune surveillance and antiviral therapy. Mechanisms such as the formation of latent reservoirs, integration into host DNA, and the establishment of episomal DNA structures enable viruses to persist despite immune and pharmacological pressure. For example, HBV cccDNA serves as an indelible template for viral replication, while HIV proviral DNA integrates into the host genome, rendering eradication by conventional means nearly impossible. Understanding these mechanisms is fundamental to the development of genome-targeted therapies like CRISPR.

Risk Factors

Risk factors for chronic infection include host immune status, viral genotype, co-infections (e.g., hepatitis D with HBV), and sociodemographic factors such as age, geographic location, and access to healthcare. Immunosuppressed individuals, including transplant recipients and those with HIV/AIDS, are particularly susceptible to chronicity and reactivation. Furthermore, behavioral and environmental factors, such as injection drug use or unprotected sexual contact, contribute to continued transmission and persistence of these infections in at-risk populations.

Clinical Features

Chronic viral infections present with a spectrum of clinical manifestations, ranging from asymptomatic carriage to severe end-organ complications. Chronic HBV may be silent for years before progressing to cirrhosis or hepatocellular carcinoma. HIV infection, if untreated, advances through stages culminating in AIDS, with susceptibility to opportunistic infections and malignancies. Chronic herpesvirus infections, such as cytomegalovirus or Epstein-Barr virus, can cause recurrent symptoms or contribute to lymphoproliferative disorders in immunocompromised hosts. Clinical vigilance and regular monitoring are essential for managing disease progression and complications.

Diagnosis

Diagnosis of chronic viral infections relies on a combination of serological, molecular, and histopathological methods. Quantitative PCR assays are the gold standard for detecting and monitoring viral load, while serology assesses immune status and exposure history. In the context of HBV, detection of HBsAg, HBeAg, and HBV DNA levels guides therapeutic decisions. For HIV, CD4 cell count and viral RNA quantification inform disease stage and treatment response. Advanced assays, such as single-cell sequencing and ultrasensitive detection of latent reservoirs, are increasingly being integrated into clinical practice to refine diagnosis and therapeutic monitoring.

Treatment & Management

Current treatment paradigms for chronic viral infections emphasize suppression of viral replication, immune modulation, and prevention of complications. Nucleos(t)ide analogues (e.g., tenofovir, entecavir) for HBV and combination antiretroviral therapy for HIV have transformed prognosis but require lifelong adherence and do not eradicate latent reservoirs. Immune-based strategies, including interferons and therapeutic vaccines, have shown variable efficacy. Despite these advances, the inability to achieve a functional cure in most patients highlights the need for innovative, mechanism-based therapies capable of eliminating persistent viral genomes.

Recent Advances / Emerging Therapies

CRISPR-Cas systems have rapidly advanced from experimental tools to potential clinical therapeutics for chronic infections. By programming sequence-specific guide RNAs, CRISPR-Cas nucleases can directly target and cleave viral DNA or RNA within infected cells. Preclinical studies have demonstrated successful excision of HBV cccDNA and HIV proviral DNA in vitro and in animal models, resulting in durable suppression or eradication of viral replication. Innovative delivery systems, such as adeno-associated virus vectors and lipid nanoparticles, have improved tissue targeting and reduced off-target effects. Recent data also suggest the feasibility of multiplexed CRISPR approaches to overcome viral genetic diversity and escape mutations. However, challenges remain regarding immune responses to Cas proteins, potential for off-target genome editing, and efficient delivery in vivo. Early-phase clinical trials are ongoing, with preliminary results indicating safety and proof-of-concept for CRISPR-based antiviral interventions.

Guideline Recommendations

While CRISPR antivirals are not yet integrated into standard clinical guidelines, major infectious disease societies recognize the promise of gene-editing technologies for future therapeutic strategies, particularly in the context of functional cure research. Current guidelines emphasize continued use of established antiviral regimens while closely monitoring developments in genome-editing therapeutics. Key considerations for future recommendations will include rigorous safety and efficacy data from controlled trials, long-term follow-up, and ethical oversight regarding germline editing and unintended effects.

Conclusion

CRISPR-based antivirals represent a transformative approach to the treatment of chronic viral infections, offering the potential for precise, durable, and possibly curative interventions. While significant scientific and clinical progress has been made, further research is needed to address delivery, specificity, and safety challenges prior to widespread clinical adoption. For healthcare professionals, awareness of emerging CRISPR-based therapies is essential for anticipating future changes in the management of chronic infections, optimizing patient care, and participating in informed discussions about the ethical, regulatory, and practical implications of genome editing in medicine.